# Neptunia A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care

**Status:** Recruiting

## Eligibility Criteria

**Sex:** Male or Female
**Age Group:** 18 years and over
This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

Adults with primarily diagnosed with Dermatomyositis (DM) or Polymyositis (PM)

**Exclusion Criteria:**

Diagnosis of myositis within 3 years of cancer

## Conditions & Interventions

**Interventions:**
Drug: M5049 high dose, Drug: Placebo
**Conditions:**
Dermatology (Skin, Hair & Nails)
**Keywords:**
Dermatomyositis (DM), Polymyositis (PM)

## More Information

**Description:** Dermatomyositis (DM) and Polymyositis (PM) are both autoimmune diseases. In autoimmune diseases, the body's immune system, which normally protects us against infection and illness, starts to attack the body's own cells instead. The main purpose of this research study is to see whether an investigational drug called enpatoran (referred to as the "study drug") works better than placebo to improve symptoms in people with DM or PM. A "placebo" looks like the study drug but does not have any active substance in it. Researchers also hope to find out more about how safe the study drug is and how well tolerated it is.
**Study Contact:** Irmina Wallander - wall0396@umn.edu
**Principal Investigator:** David Pearson
**IRB Number:** SITE00001761